STALE?Report written 16 days ago · at $87.72entry levels may be stale — re-check before acting

CELC

MoonshotMID CAP

Celcuity Inc. · NASDAQ · Healthcare / Biotechnology

$87.72

▲ 1.55%

MCap $4.28B

Approved Jul 14, 2026 — 3 days ahead of the Jul 17 PDUFA date — but the stock round-tripped: a +7% approval-day pop was erased by a -15% to -17.6% single-session slide when management guided commercial launch to "late Q3 2026" instead of sooner. Now roughly flat vs the pre-approval $90 screen price and down ~42% from the May 2026 all-time high of $151.02

BusinessOncology biotech · REVTORPYK (gedatolisib) — first FDA-approved pan-PI3K/mTOR inhibitor for HR+/HER2-/PIK3CA wild-type advanced breast cancer (approved Jul 14, 2026) · Commercial launch guided to late Q3 2026 · PIK3CA-mutant label-expansion sNDA targeted Q3 2026

Thesis

Celcuity's gedatolisib (branded REVTORPYK) won FDA approval on July 14, 2026 for HR+/HER2-/PIK3CA wild-type advanced breast cancer, becoming the company's first commercial product — the binary regulatory catalyst that anchored the original thesis has resolved cleanly. But the stock round-tripped violently: a same-day +7% pop was erased by a -15% to -17.6% slide when management guided commercial launch to "late Q3 2026" (delayed vs prior expectations, citing drug-supply readiness), which also triggered active securities-fraud investigations by multiple law firms (no lawsuit filed yet). With Q2 earnings due Aug 6, 2026 and a PIK3CA-mutant sNDA targeted for Q3 2026 to expand the label, the thesis has shifted from "will it get approved" to "can it execute a clean commercial launch without further stumbles." Still a ค่าขนม binary — size 2-3% max — but the swing factor is now execution and litigation overhang, not regulatory risk.

📝 Primary Verdict · Core Holding

SPECULATIVEMoonshot

ค่าขนม SPECULATIVE — the Jul 17 PDUFA binary already resolved (approved Jul 14), but the stock round-tripped on delayed Q3 launch guidance + a fraud-investigation overhang. Aug 6 Q2 earnings is the next tell. Base ~$110 (+25%) on steady launch execution, Bull ~$145 (+65%) toward analyst consensus, Moon ~$189 (+115%) on mutant-label progress + a clean beat. Size 2-3% max — the risk driver has moved from regulatory to execution/litigation, not away.

88

score / 100 ⓘ

⚡ Catalyst

📊 Q2 2026 Earnings2 DAYS

First quarterly print since the Jul 14 approval. Investors want commentary on Q3 launch readiness, drug supply timeline, payer/formulary access progress, and cash runway following the $500M convertible note raise.

Aug 6, 2026

🚀 Commercial Launch — REVTORPYK (WT Indication)LATE Q3 2026

Management now guides U.S. commercial launch to late Q3 2026 (delayed vs earlier expectations) to ensure adequate product supply. This guidance shift already cost the stock ~15-18% in one session on Jul 15 — a clean, on-time launch is now the key re-rate trigger.

Late Q3 2026

🧬 PIK3CA-Mutant Cohort — sNDA FilingQ3 2026

Celcuity plans to submit a supplemental NDA in Q3 2026 for the PIK3CA-mutant population, based on VIKTORIA-1 mutant-cohort data (PFS HR 0.50 vs alpelisib + fulvestrant). This is the larger addressable population beyond the WT-only label just approved; regulatory decision expected ~2027.

Q3 2026

🔬 VIKTORIA-2 — First-Line Expansion TrialONGOING

Phase 3 trial (n~1,180) evaluating gedatolisib + CDK4/6 inhibitor + fulvestrant as first-line treatment for endocrine-resistant HR+/HER2- ABC. Long-dated pipeline optionality beyond the two indications already in motion.

2027+

🎯 Entry Point

Entry 1

$87.72

Current price — post-approval, pre-launch, litigation overhang not yet resolvedNow (2-3% max)

Entry 2PREFERRED

$75–80

Pre-earnings dip zone into the Aug 6 Q2 print — preferred if broader market wobblesIf dips into earnings

Entry 3

$61.40

Post-selloff / litigation-headline crash zone — only for high-conviction re-entry if launch guidance still intactIf sector selloff or lawsuit-filing headline

✅ Take Profit

TP1

Base — launch executes on the late-Q3 timeline, market regains confidence

$109.65

+25%

TP2

Bull — commercial ramp proves out, stock approaches analyst consensus (~$163)

$144.74

+65%

TP3 🌙

Moon — mutant-cohort sNDA path derisks + beat-and-raise launch, stock revisits/exceeds the $151 52-wk high

$188.6

+115%

🔴 Stop Loss

Tight Stop

Breach of post-selloff support without new bad news — thesis souring on launch-execution doubt

$68

-22.5%

Hard Stop

Litigation materializes into an actually-filed suit, or Q3 launch slips again — thesis-changing, not just sentiment

$61.4

-30%

Risk / Reward

Preferred entry ($75-80) vs TP2 ($144.74), risk sized to the tight stop ($68), not the litigation/relaunch-delay tail risk

7.1 : 1

⚠ Regulatory binary has resolved — this is now execution + litigation-overhang risk, size accordingly ✅

📅 Estimate Date

Q2 2026 Earnings

First commentary on Q3 launch readiness, drug supply, payer access, and cash position post-approval

Aug 6, 2026

Launch readiness update

Commercial Launch — REVTORPYK

Delayed from earlier expectations — company cites need for adequate drug supply

Late Q3 2026

Contingent on supply ramp executing on time

PIK3CA-Mutant sNDA Submission

Based on VIKTORIA-1 mutant cohort (PFS HR 0.50 vs alpelisib) — expands label beyond WT-only approval

Q3 2026

Regulatory decision ~2027

📈 Possible Up % — Scenario Spread

Bear

-30%

$61.4

Base

+25%

$109.65

Bull

+65%

$144.74

Moon

+115%

$188.6

← downsideupside →

🏛️ Fed / Macro Risk — LOW

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook

Fed held at 3.50-3.75% on Jul 29, 2026 with 3 hawkish dissents favoring a hike — rate-hike tail risk into year-end hasn't gone away, but CELC's own approval-and-launch news flow dominates the stock's direction far more than Fed policy.

Inflation

Core PCE still 3.3% YoY, well above the 2% target. Oncology drug pricing is largely insulated from near-term CPI prints; payer/formulary negotiation and launch execution matter more.

Sector Impact

LOW direct Fed impact on CELC's launch-execution catalyst. The hawkish-Fed backdrop compresses high-multiple biotech valuations broadly, but a clean Q3 launch plus a strong Aug 6 print would likely override sector headwinds; a second guidance disappointment would not get the benefit of the doubt.

Summary

Fed risk is LOW for CELC specifically — the regulatory binary has already resolved and the next catalysts (Aug 6 earnings, Q3 launch) are company-specific execution events. Sector-wide biotech multiple compression is a secondary headwind, not the driver of CELC's price action.

🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Consensus (12 analysts)

Strong Buy$163.45+86%

Craig-Hallum

Buy$178+103%

H.C. Wainwright

Buy$155+77%

Wells Fargo

Overweight$166+89%

current price $87.72

🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

CELC⚡ MixedJul 2026

-18%

in 1 day

Own Jul 14-15, 2026 approval-then-guidance round trip

The most directly relevant precedent for the Aug 6 / Q3 launch catalyst is CELC's own recent history: +7% on the approval headline, then -15% to -17.6% the next session purely on a delayed launch timeline. This stock has already shown it will punish execution guidance as hard as a clinical miss.

TVTX✅ GoodApr 2026

+34%

in 1 day

Filspari FDA Approval — Expanded FSGS Label

Day-1 +34% on a rare-disease/oncology-adjacent biologic approval with a clean, on-schedule launch story — the outcome CELC needs from its own Q3 launch to re-rate toward the ~$163 analyst consensus.

MRUS⚡ MixedDec 2024

+2%

in 1 day

Bizengri FDA Accelerated Approval — NRG1+ NSCLC/Pancreatic

Cautionary sell-the-news comp: MRUS rose only +1.8% on its first FDA approval because optimism was largely pre-priced — the same dynamic that made CELC's own approval-day pop fragile against any bad guidance.

⚡ Optional Layer · Tactical Overlay

🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-22.5% / -30%) only when trading the earnings spot — not for the core holding (use the -22.5% / -30% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern

+7% (approval day) / -15% to -17.6% (guidance day) — already realized, not still to comeOngoing — Aug 6 earnings is the next scheduled data point; the launch itself is the Q3 event

Post-approval, CELC has already booked both directions in real time — a same-day +7% pop on the Jul 14 approval headline, erased by a -15% to -17.6% slide the next day when management guided commercial launch to "late Q3 2026" instead of sooner. Into the Aug 6 earnings print and the Q3 launch window, expect continued headline sensitivity rather than a steady pre-event drift.

🎲Historical Post-Catalyst Move

✅ Catalyst Winavg +34%

range: +15% to +46%· Apr 2026 (TVTX)

Reference case: Travere's Filspari FSGS approval (Apr 2026) rose +34% day-1, extending to +46% over 30 days as launch execution matched or beat expectations — the playbook CELC needs to replicate with its own Q3 launch to re-rate back toward the ~$163 analyst consensus.

❌ Catalyst Missavg -16%

range: -15% to -18%· Jul 15, 2026 (CELC guidance-driven selloff)

CELC's own Jul 15, 2026 reaction is the direct precedent: shares fell ~15-17.6% in a single session purely on a delayed launch timeline (late Q3 vs expected sooner), even with a clean FDA approval already in hand — proof this stock punishes execution/timeline slips as hard as clinical failures.

💼Spot Position Sizing

How the recommended % is derived

3%

of portfolio

3% max — the regulatory binary has resolved (approved), but the stock is now trading on commercial-execution risk, active securities-fraud investigations (unfiled, but a real overhang), and a Q3 launch timeline that already disappointed once. Not a clean de-risked story yet.

🛑Stop Loss · Spot Trade

Spot cut-loss levels — separate from the core holding

Before Catalyst

-22.5%($68)

หลุด $68 ก่อน Aug 6 earnings / Q3 launch = conviction เปลี่ยน แม้ approval จะผ่านไปแล้ว

After Catalyst (Bad Result)-30%

ถ้า Q3 launch เลื่อนอีกรอบ หรือมี lawsuit ยื่นจริง (ไม่ใช่แค่ investigation) = exit ทันที

📎 Sources

https://ir.celcuity.com/news-releases/news-release-details/celcuity-announces-fda-approval-revtorpyktm-gedatolisib https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally https://stockanalysis.com/stocks/celc/https://money.usnews.com/investing/news/articles/2026-07-15/celcuity-shares-fall-as-delayed-breast-cancer-drug-launch-eclipses-first-us-fda-approval https://www.globenewswire.com/news-release/2026/07/21/3330168/0/en/CELC-INVESTOR-ALERT-Kirby-McInerney-LLP-Announces-Investigation-Into-Potential-Securities-Fraud.html https://finance.yahoo.com/sectors/healthcare/articles/celcuity-celc-weighs-dilution-against-191120548.html https://www.investing.com/news/analyst-ratings/celcuity-stock-price-target-raised-to-155-by-hc-wainwright-on-fda-approval-93CH-4793281 https://seekingalpha.com/news/4614082-celcuity-falls-despite-fda-nod-breast-cancer-drug

Generated 2026-08-04 · Not financial advice